がん溶解性ウイルス療法の世界市場レポート 2025年

がん溶解性ウイルス療法の市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR23.7％で5億5,000万米ドルに成長します。予測期間の成長は、オンコリティックウイルスプラットフォームの拡大、免疫チェックポイント阻害剤との併用療法、個別化医療アプローチ、臨床試験状況の拡大、規制支援、ガイドラインに起因すると考えられます。予測期間における主な動向としては、デリバリーシステムの技術的進歩、合成生物学の進歩、バイオ医薬品業界における共同研究や提携、ウイルス学や免疫学の進歩、小児がんへの注力などが挙げられます。

がん患者の急増ががん溶解性ウイルス療法市場の成長を牽引します。がんは、制御不能な細胞増殖を特徴とする疾患の総称であり、世界的に重大な健康問題です。がん溶解性ウイルス療法は、がん細胞を選択的に標的にして排除すると同時に、腫瘍に対する免疫反応を誘発することができ、効果的ながん治療のための二重メカニズムを提供する有望なアプローチとして浮上しています。注目すべきことに、2023年1月、米国がん協会（American Cancer Society Inc.）は、2022年の米国におけるがん死亡者数を609,820人、新規がん罹患者数を1,958,310人と予測しました。この厳しい現実は、がん溶解性ウイルス療法のような革新的な治療アプローチが、増大するがん患者の有病率に対処するために緊急に必要であることを強調しています。

がん溶解性ウイルス療法市場は、進行中の臨床試験の増加に後押しされて成長すると予想されます。臨床試験は、新しい治療、介入、診断方法の安全性と有効性を評価するための、ヒトを対象とした重要な調査研究です。がん溶解性ウイルス療法を利用した臨床試験の急増は、健康な組織を温存しながらがん細胞を選択的に標的にする能力を持つこのアプローチの治療的可能性を強調しています。2023年10月現在、ClinicalTrials.govは、登録された試験の大幅な増加を報告しており、2022年の437,523件から、米国50州および221カ国全体で468,457件に増加しています。注目すべきは、143,613試験（全体の31％）が米国で登録され、251,159試験（全体の54％）が米国以外で登録されていることです。このような臨床試験の急増は、がん治療の有望な手段としてがん溶解性ウイルス療法への関心と投資が高まっていることを意味し、市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界がん溶解性ウイルス療法PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のがん溶解性ウイルス療法市場：成長率分析
• 世界のがん溶解性ウイルス療法市場の実績：規模と成長, 2019-2024
• 世界のがん溶解性ウイルス療法市場の予測：規模と成長, 2024-2029, 2034F
• 世界がん溶解性ウイルス療法総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のがん溶解性ウイルス療法市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• HSVベースのがん溶解性ウイルス療法
• アデノウイルスベースのがん溶解性ウイルス療法
• レオウイルス
• ポックスウイルス
• NDV（ニューカッスル病ウイルス）
• その他の治療法
• 世界のがん溶解性ウイルス療法市場ウイルスの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子組み換え腫瘍溶解性ウイルス
• 腫瘍溶解性野生型ウイルス
• 世界のがん溶解性ウイルス療法市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 肺がん
• 前立腺がん
• 悪性黒色腫
• 脳腫瘍
• 血液がん
• 世界のがん溶解性ウイルス療法市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• がん調査機関
• 世界のがん溶解性ウイルス療法市場、HSVベースの腫瘍溶解性ウイルス療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タリモジーン・ラヘルパレプベク（T-VEC）
• その他のHSVベースの治療法
• 世界のがん溶解性ウイルス療法市場アデノウイルスベースの腫瘍溶解性ウイルス療法の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オニキス-015
• アドV-5/3-D24
• その他のアデノウイルスベースの治療法
• 世界のがん溶解性ウイルス療法市場、レオウイルスのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• レオリシン
• その他のレオウイルス治療法
• 世界のがん溶解性ウイルス療法市場、ポックスウイルスのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• JX-594（オンコバック）
• その他のポックスウイルス治療法
• 世界のがん溶解性ウイルス療法市場NDV（ニューカッスル病ウイルス）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• NDVベースの治療法
• その他のNDVアプリケーション
• 世界のがん溶解性ウイルス療法市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 併用療法
• その他の新たな腫瘍溶解性ウイルス療法

第7章 地域別・国別分析

• 世界のがん溶解性ウイルス療法市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のがん溶解性ウイルス療法市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がん溶解性ウイルス療法市場：競合情勢
• がん溶解性ウイルス療法市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Sorrento Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Boehringer Ingelheim Group
• Regeneron Pharmaceuticals
• Daiichi Sankyo Company Limited
• Kissei Pharmaceutical Co. Ltd.
• Takara Bio Inc.
• Oncorus Inc.
• Replimune Inc.
• Vyriad Inc.
• Genelux Corporation
• Oncolys BioPharma Inc.
• Adze Biotechnology
• Oncolytics Biotech Inc.
• TILT Biotherapeutics Ltd.
• Transgene SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• がん溶解性ウイルス療法市場2029：新たな機会を提供する国
• がん溶解性ウイルス療法市場2029：新たな機会を提供するセグメント
• がん溶解性ウイルス療法市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Oncolytic virus therapy, also referred to as virotherapy, represents a cancer treatment approach employing viruses to selectively target and eliminate cancer cells within the body. The primary goal of this therapy is to leverage modified or naturally occurring viruses capable of infecting and replicating specifically within cancerous cells while preserving healthy cells.

The key categories of oncolytic virus therapy include HSV-based oncolytic virus therapy, adenovirus-based oncolytic virus therapy, reovirus, poxviruses, Newcastle disease virus (NDV), among others. HSV-based oncolytic virus therapy employs the herpes simplex virus (HSV) as the foundational component for treatment. Various virus types encompass genetically modified oncolytic viruses as well as oncolytic wild-type viruses. These therapies find application across different cancer types such as breast cancer, lung cancer, prostate cancer, melanoma, brain tumors, and blood cancer. They are utilized by healthcare institutions including hospitals, specialized clinics, and cancer research institutes.

The oncolytic virus therapy market research report is one of a series of new reports from The Business Research Company that provides oncolytic virus therapy market statistics, including oncolytic virus therapy industry global market size, regional shares, competitors with an oncolytic virus therapy market share, detailed oncolytic virus therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oncolytic virus therapy industry. This oncolytic virus therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncolytic virus therapy market size has grown exponentially in recent years. It will grow from $0.19 billion in 2024 to $0.23 billion in 2025 at a compound annual growth rate (CAGR) of 25.4%. The growth in the historic period can be attributed to improved genetic engineering techniques, increased understanding of tumor microenvironment, clinical successes and regulatory approvals, the rise of immunotherapy in cancer treatment, and advancements in gene delivery systems

The oncolytic virus therapy market size is expected to see exponential growth in the next few years. It will grow to $0.55 billion in 2029 at a compound annual growth rate (CAGR) of 23.7%. The growth in the forecast period can be attributed to the expansion of oncolytic virus platforms, combination therapies with immune checkpoint inhibitors, personalized medicine approaches, expansion of the clinical trial landscape, regulatory support and guidelines. Major trends in the forecast period include technological advances in delivery systems, advancements in synthetic biology, collaborations and partnerships in the biopharmaceutical industry, advancements in virology and immunology, focus on pediatric oncology.

The escalating prevalence of cancer cases stands poised to drive the growth of the oncolytic virus therapy market. Cancer, a collective term for diseases characterized by uncontrolled cell growth, is a significant global health concern. Oncolytic virus therapy emerges as a promising approach, capable of selectively targeting and eliminating cancer cells while simultaneously triggering an immune response against tumors, providing a dual mechanism for effective cancer treatment. Notably, in January 2023, the American Cancer Society Inc. projected 609,820 cancer deaths and 1,958,310 new cancer cases in the United States for 2022. This stark reality underscores the urgent need for innovative therapeutic approaches, such as oncolytic virus therapy, to address the growing prevalence of cancer cases.

The oncolytic virus therapy market is expected to experience growth propelled by the increasing number of ongoing clinical trials. Clinical trials, essential research studies involving human participants, serve to assess the safety and efficacy of new medical treatments, interventions, or diagnostic procedures. The surge in clinical trials utilizing oncolytic virus therapy underscores the therapeutic potential of this approach, given its ability to selectively target cancer cells while sparing healthy tissue. As of October 2023, ClinicalTrials.gov reported a significant increase in registered studies, rising from 437,523 in 2022 to 468,457 across all 50 states of the United States and 221 countries. Notably, 143,613 studies (31% of the total) are registered in the U.S., with 251,159 studies (54% of the total) registered in non-U.S. locations. This proliferation of clinical trials signifies the growing interest and investment in oncolytic virus therapy as a promising avenue for cancer treatment, contributing to the market's expansion.

Major companies in the oncolytic virus therapy market are focused on securing regulatory approvals to accelerate the launch of innovative cancer treatments. Regulatory approvals refer to the procedure through which health authorities assess and authorize medical products, including drugs, biologics, and medical devices, for market use. For example, in March 2024, ImmVira, a biotechnology firm based in China, received Fast Track designation from the FDA for its oncolytic virus therapy, MVR-T3011 IT. This therapy is intended for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have experienced disease progression after platinum-based chemotherapy and at least one prior line of anti-PD-1/PD-L1 therapy. The Fast Track designation aims to expedite the development and review process for therapies that address serious conditions with unmet medical needs.

Strategic partnerships play a pivotal role in advancing comprehensive cancer treatments within the oncolytic virus therapy industry. RenovoRx Inc., a US-based clinical-stage biopharmaceutical company, and Imugene Ltd., an Australia-based clinical-stage immuno-oncology company, forged a strategic research collaboration in July 2023. The aim of this partnership is to optimize the delivery of Imugene's oncolytic virus therapy leveraging RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform. Additionally, the collaboration seeks to explore the administration of Imugene's CF33 oncolytic virus technology using RenovoRx's TAMP therapy platform, with a specific focus on treating challenging-to-access tumors. This strategic alliance exemplifies the industry's commitment to collaborative efforts, driving advancements in oncolytic virus therapy for enhanced cancer treatment outcomes.

In April 2022, Recipharm AB, a pharmaceutical company based in Sweden, completed the acquisition of Vibalogics for an undisclosed sum. This strategic move enabled Recipharm AB to enhance its global presence significantly by integrating a comprehensive end-to-end portfolio encompassing development capabilities, GMP drug substance and drug product manufacturing, sterile fill & finish services, as well as analytical and quality control testing. Vibalogics, a German biotechnology firm and a Contract Development and Manufacturing Organization (CDMO), specializes in manufacturing oncolytic viruses, viral vaccines, and gene therapies.

Major companies operating in the oncolytic virus therapy market include Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics

North America was the largest region in the oncolytic virus therapy market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the oncolytic virus therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oncolytic virus therapy market includes revenues earned by entities by providing seneca valley virus (SVV), semliki forest virus (SFV), vesicular stomatitis virus (VSV), and sindbis virus (SBV). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncolytic Virus Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncolytic virus therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncolytic virus therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncolytic virus therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy Type: HSV-Based Oncolytic Virus Therapy; Adenovirus-Based Oncolytic Virus Therapy; Reovirus; Poxviruses; NDV (Newcastle Disease Virus); Other Therapy Types
• 2) By Virus Type: Genetically Engineered Oncolytic Viruses; Oncolytic Wild-Type Viruses
• 3) By Application: Breast Cancer; Lung Cancer; Prostate Cancer; Melanoma; Brain Tumor; Blood Cancer
• 4) By End-User: Hospitals; Specialty Clinics; Cancer Research Institutes
• Subsegments:
• 1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC); Other HSV-Based Therapies
• 2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015; AdV-5/3-D24; Other Adenovirus-Based Therapies
• 3) By Reovirus: Reolysin; Other Reovirus Therapies
• 4) By Poxviruses: JX-594 (OncoVac); Other Poxvirus Therapies
• 5) By NDV (Newcastle Disease Virus): NDV-Based Therapies; Other NDV Applications
• 6) By Other Therapy Types: Combination Therapies; Other Emerging Oncolytic Virus Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Sorrento Therapeutics Inc.; AbbVie Inc.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncolytic Virus Therapy Market Characteristics

3. Oncolytic Virus Therapy Market Trends And Strategies

4. Oncolytic Virus Therapy Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Oncolytic Virus Therapy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oncolytic Virus Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oncolytic Virus Therapy Market Growth Rate Analysis
• 5.4. Global Oncolytic Virus Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oncolytic Virus Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oncolytic Virus Therapy Total Addressable Market (TAM)

6. Oncolytic Virus Therapy Market Segmentation

• 6.1. Global Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HSV-Based Oncolytic Virus Therapy
• Adenovirus-Based Oncolytic Virus Therapy
• Reovirus
• Poxviruses
• NDV (Newcastle Disease Virus)
• Other Therapy Types
• 6.2. Global Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetically Engineered Oncolytic Viruses
• Oncolytic Wild-Type Viruses
• 6.3. Global Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Melanoma
• Brain Tumor
• Blood Cancer
• 6.4. Global Oncolytic Virus Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Cancer Research Institutes
• 6.5. Global Oncolytic Virus Therapy Market, Sub-Segmentation Of HSV-Based Oncolytic Virus Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Talimogene Laherparepvec (T-VEC)
• Other HSV-Based Therapies
• 6.6. Global Oncolytic Virus Therapy Market, Sub-Segmentation Of Adenovirus-Based Oncolytic Virus Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Onyx-015
• AdV-5/3-D24
• Other Adenovirus-Based Therapies
• 6.7. Global Oncolytic Virus Therapy Market, Sub-Segmentation Of Reovirus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reolysin
• Other Reovirus Therapies
• 6.8. Global Oncolytic Virus Therapy Market, Sub-Segmentation Of Poxviruses, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• JX-594 (OncoVac)
• Other Poxvirus Therapies
• 6.9. Global Oncolytic Virus Therapy Market, Sub-Segmentation Of NDV (Newcastle Disease Virus), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• NDV-Based Therapies
• Other NDV Applications
• 6.10. Global Oncolytic Virus Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Therapies
• Other Emerging Oncolytic Virus Therapies

7. Oncolytic Virus Therapy Market Regional And Country Analysis

• 7.1. Global Oncolytic Virus Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oncolytic Virus Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncolytic Virus Therapy Market

• 8.1. Asia-Pacific Oncolytic Virus Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncolytic Virus Therapy Market

• 9.1. China Oncolytic Virus Therapy Market Overview
• 9.2. China Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncolytic Virus Therapy Market

• 10.1. India Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncolytic Virus Therapy Market

• 11.1. Japan Oncolytic Virus Therapy Market Overview
• 11.2. Japan Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncolytic Virus Therapy Market

• 12.1. Australia Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncolytic Virus Therapy Market

• 13.1. Indonesia Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncolytic Virus Therapy Market

• 14.1. South Korea Oncolytic Virus Therapy Market Overview
• 14.2. South Korea Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncolytic Virus Therapy Market

• 15.1. Western Europe Oncolytic Virus Therapy Market Overview
• 15.2. Western Europe Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncolytic Virus Therapy Market

• 16.1. UK Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncolytic Virus Therapy Market

• 17.1. Germany Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncolytic Virus Therapy Market

• 18.1. France Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncolytic Virus Therapy Market

• 19.1. Italy Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncolytic Virus Therapy Market

• 20.1. Spain Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncolytic Virus Therapy Market

• 21.1. Eastern Europe Oncolytic Virus Therapy Market Overview
• 21.2. Eastern Europe Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncolytic Virus Therapy Market

• 22.1. Russia Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncolytic Virus Therapy Market

• 23.1. North America Oncolytic Virus Therapy Market Overview
• 23.2. North America Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncolytic Virus Therapy Market

• 24.1. USA Oncolytic Virus Therapy Market Overview
• 24.2. USA Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncolytic Virus Therapy Market

• 25.1. Canada Oncolytic Virus Therapy Market Overview
• 25.2. Canada Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncolytic Virus Therapy Market

• 26.1. South America Oncolytic Virus Therapy Market Overview
• 26.2. South America Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncolytic Virus Therapy Market

• 27.1. Brazil Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncolytic Virus Therapy Market

• 28.1. Middle East Oncolytic Virus Therapy Market Overview
• 28.2. Middle East Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncolytic Virus Therapy Market

• 29.1. Africa Oncolytic Virus Therapy Market Overview
• 29.2. Africa Oncolytic Virus Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oncolytic Virus Therapy Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oncolytic Virus Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncolytic Virus Therapy Market Competitive Landscape And Company Profiles

• 30.1. Oncolytic Virus Therapy Market Competitive Landscape
• 30.2. Oncolytic Virus Therapy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sorrento Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Oncolytic Virus Therapy Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Boehringer Ingelheim Group
• 31.3. Regeneron Pharmaceuticals
• 31.4. Daiichi Sankyo Company Limited
• 31.5. Kissei Pharmaceutical Co. Ltd.
• 31.6. Takara Bio Inc.
• 31.7. Oncorus Inc.
• 31.8. Replimune Inc.
• 31.9. Vyriad Inc.
• 31.10. Genelux Corporation
• 31.11. Oncolys BioPharma Inc.
• 31.12. Adze Biotechnology
• 31.13. Oncolytics Biotech Inc.
• 31.14. TILT Biotherapeutics Ltd.
• 31.15. Transgene SA

32. Global Oncolytic Virus Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncolytic Virus Therapy Market

34. Recent Developments In The Oncolytic Virus Therapy Market

35. Oncolytic Virus Therapy Market High Potential Countries, Segments and Strategies

• 35.1 Oncolytic Virus Therapy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oncolytic Virus Therapy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oncolytic Virus Therapy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer